Literature DB >> 24390149

Utility of 3-dimensional echocardiography, global longitudinal strain, and exercise stress echocardiography to detect cardiac dysfunction in breast cancer patients treated with doxorubicin-containing adjuvant therapy.

Michel G Khouri1, Whitney E Hornsby, Niels Risum, Eric J Velazquez, Samantha Thomas, Amy Lane, Jessica M Scott, Graeme J Koelwyn, James E Herndon, John R Mackey, Pamela S Douglas, Lee W Jones.   

Abstract

Conventional resting left ventricular ejection fraction (LVEF) assessments have limitations for detecting doxorubicin (DOX)-related cardiac dysfunction. Novel resting echocardiographic parameters, including 3-dimensional echocardiography (3DE) and global longitudinal strain (GLS), have potential for early identification of chemotherapy-related myocardial injury. Exercise "stress" is an established method to uncover impairments in cardiac function but has received limited attention in the adult oncology setting. We evaluated the utility of an integrated approach using 3DE, GLS, and exercise stress echocardiography for detecting subclinical cardiac dysfunction in early breast cancer patients treated with DOX-containing chemotherapy. Fifty-seven asymptomatic women with early breast cancer (mean 26 ± 22 months post-chemotherapy) and 20 sex-matched controls were studied. Resting left ventricular (LV) function was assessed by LVEF using 2-dimensional echocardiography (2DE) and 3DE and by GLS using 2-dimensional speckle-tracking echocardiography (2D-STE). After resting assessments, subjects completed cardiopulmonary exercise testing with stress 2DE. Resting LVEF was lower in patients than controls by 3DE (55 ± 4 vs. 59 ± 5 %; p = 0.005) but not 2DE (56 ± 4 vs. 58 ± 3 %; p = 0.169). 10 of 51 (20 %) patients had GLS greater than or equal to -17 %, which was below the calculated lower limit of normal (control mean 2SD); this patient subgroup had a mean 20 % impairment in GLS (-16.1 ± 0.9 vs. -20.1 ± 1.5 %; p < 0.001), despite similar LVEF by 2DE and 3DE compared to controls (p > 0.05). Cardiopulmonary function (VO2peak) was 20 % lower in patients than controls (p < 0.001). Exercise stress 2DE assessments of stroke volume (61 ± 11 vs. 69 ± 15 ml; p = 0.018) and cardiac index (2.3 ± 0.9 vs. 3.1 ± 0.8 l min(-1) m(-2) mean increase; p = 0.003) were lower in patients than controls. Post-exercise increase in cardiac index predicted VO2peak (r = 0.429, p = 0.001). Resting 3DE, GLS, and exercise stress 2DE detect subclinical cardiac dysfunction not apparent with resting 2DE in post-DOX breast cancer patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24390149      PMCID: PMC4521213          DOI: 10.1007/s10549-013-2818-1

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  42 in total

Review 1.  Echocardiographic assessment of myocardial strain.

Authors:  John Gorcsan; Hidekazu Tanaka
Journal:  J Am Coll Cardiol       Date:  2011-09-27       Impact factor: 24.094

2.  EAE/ASE recommendations for image acquisition and display using three-dimensional echocardiography.

Authors:  Roberto M Lang; Luigi P Badano; Wendy Tsang; David H Adams; Eustachio Agricola; Thomas Buck; Francesco F Faletra; Andreas Franke; Judy Hung; Leopoldo Pérez de Isla; Otto Kamp; Jaroslaw D Kasprzak; Patrizio Lancellotti; Thomas H Marwick; Marti L McCulloch; Mark J Monaghan; Petros Nihoyannopoulos; Natesa G Pandian; Patricia A Pellikka; Mauro Pepi; David A Roberson; Stanton K Shernan; Girish S Shirali; Lissa Sugeng; Folkert J Ten Cate; Mani A Vannan; Jose Luis Zamorano; William A Zoghbi
Journal:  J Am Soc Echocardiogr       Date:  2012-01       Impact factor: 5.251

3.  Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.

Authors:  Heloisa Sawaya; Igal A Sebag; Juan Carlos Plana; James L Januzzi; Bonnie Ky; Timothy C Tan; Victor Cohen; Jose Banchs; Joseph R Carver; Susan E Wiegers; Randolph P Martin; Michael H Picard; Robert E Gerszten; Elkan F Halpern; Jonathan Passeri; Irene Kuter; Marielle Scherrer-Crosbie
Journal:  Circ Cardiovasc Imaging       Date:  2012-06-28       Impact factor: 7.792

4.  The utility of cardiac biomarkers, tissue velocity and strain imaging, and cardiac magnetic resonance imaging in predicting early left ventricular dysfunction in patients with human epidermal growth factor receptor II-positive breast cancer treated with adjuvant trastuzumab therapy.

Authors:  Nazanin Fallah-Rad; Jonathan R Walker; Anthony Wassef; Matthew Lytwyn; Sheena Bohonis; Tielan Fang; Ganhong Tian; Iain D C Kirkpatrick; Pawan K Singal; Marianne Krahn; Debjani Grenier; Davinder S Jassal
Journal:  J Am Coll Cardiol       Date:  2011-05-31       Impact factor: 24.094

5.  Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer.

Authors:  Lee W Jones; Whitney E Hornsby; Amy Goetzinger; Lindsay M Forbes; Emily L Sherrard; Morten Quist; Amy T Lane; Miranda West; Neil D Eves; Margaret Gradison; April Coan; James E Herndon; Amy P Abernethy
Journal:  Lung Cancer       Date:  2011-11-22       Impact factor: 5.705

6.  Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum.

Authors:  Lee W Jones; Kerry S Courneya; John R Mackey; Hyman B Muss; Edith N Pituskin; Jessica M Scott; Whitney E Hornsby; April D Coan; James E Herndon; Pamela S Douglas; Mark Haykowsky
Journal:  J Clin Oncol       Date:  2012-05-21       Impact factor: 44.544

Review 7.  Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology.

Authors:  Thomas Eschenhagen; Thomas Force; Michael S Ewer; Gilles W de Keulenaer; Thomas M Suter; Stefan D Anker; Metin Avkiran; Evandro de Azambuja; Jean-Luc Balligand; Dirk L Brutsaert; Gianluigi Condorelli; Arne Hansen; Stephane Heymans; Joseph A Hill; Emilio Hirsch; Denise Hilfiker-Kleiner; Stefan Janssens; Steven de Jong; Gitte Neubauer; Burkert Pieske; Piotr Ponikowski; Munir Pirmohamed; Mathias Rauchhaus; Douglas Sawyer; Peter H Sugden; Johann Wojta; Faiez Zannad; Ajay M Shah
Journal:  Eur J Heart Fail       Date:  2011-01       Impact factor: 15.534

8.  Cardiorespiratory fitness and classification of risk of cardiovascular disease mortality.

Authors:  Sachin Gupta; Anand Rohatgi; Colby R Ayers; Benjamin L Willis; William L Haskell; Amit Khera; Mark H Drazner; James A de Lemos; Jarett D Berry
Journal:  Circulation       Date:  2011-03-21       Impact factor: 29.690

Review 9.  Cancer therapy-induced cardiac toxicity in early breast cancer: addressing the unresolved issues.

Authors:  Michel G Khouri; Pamela S Douglas; John R Mackey; Miguel Martin; Jessica M Scott; Marielle Scherrer-Crosbie; Lee W Jones
Journal:  Circulation       Date:  2012-12-04       Impact factor: 29.690

Review 10.  Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction.

Authors:  Jennifer B Christian; John K Finkle; Bonnie Ky; Pamela S Douglas; David E Gutstein; Paul D Hockings; Pierre Lainee; Daniel J Lenihan; Jay W Mason; Philip T Sager; Thomas G Todaro; Karen A Hicks; Robert C Kane; Hon-Sum Ko; JoAnn Lindenfeld; Eric L Michelson; James Milligan; Jiefen Y Munley; Joel S Raichlen; Amir Shahlaee; Colette Strnadova; Brenda Ye; J Rick Turner
Journal:  Am Heart J       Date:  2012-10-26       Impact factor: 4.749

View more
  16 in total

Review 1.  Exercise Therapy and Cardiovascular Toxicity in Cancer.

Authors:  Jessica M Scott; Tormod S Nilsen; Dipti Gupta; Lee W Jones
Journal:  Circulation       Date:  2018-03-13       Impact factor: 29.690

2.  Cardiac Atrophy and Heart Failure In Cancer.

Authors:  Mark Sweeney; Angela Yiu; Alexander R Lyon
Journal:  Card Fail Rev       Date:  2017-04

3.  Breast cancer survivors with preserved or rescued cardiorespiratory fitness have similar cardiac, pulmonary and muscle function compared to controls.

Authors:  Georgios Grigoriadis; Sara R Sherman; Natalia S Lima; Elizabeth C Lefferts; Brooks A Hibner; Hannah C Ozemek; Oana C Danciu; Dimitra Kanaloupitis; Bo Fernhall; Tracy Baynard
Journal:  Eur J Appl Physiol       Date:  2022-07-07       Impact factor: 3.346

4.  Validity of Estimated Cardiorespiratory Fitness in Patients With Primary Breast Cancer.

Authors:  Meghan Michalski; Kylie Rowed; Jessica A Lavery; Chaya S Moskowitz; Catherine Capaci; Guro Stene; Elisabeth Edvardsen; Neil D Eves; Lee W Jones; Jessica M Scott
Journal:  JACC CardioOncol       Date:  2022-06-21

Review 5.  Cardiovascular Late Effects and Exercise Treatment in Breast Cancer: Current Evidence and Future Directions.

Authors:  Jessica M Scott; Scott C Adams; Graeme J Koelwyn; Lee W Jones
Journal:  Can J Cardiol       Date:  2016-04-01       Impact factor: 5.223

Review 6.  Current and emerging modalities for detection of cardiotoxicity in cardio-oncology.

Authors:  Michel G Khouri; Michael R Klein; Eric J Velazquez; Lee W Jones
Journal:  Future Cardiol       Date:  2015-08-03

7.  Ventricular-Arterial Coupling in Breast Cancer Patients After Treatment With Anthracycline-Containing Adjuvant Chemotherapy.

Authors:  Graeme J Koelwyn; Nia C Lewis; Susan L Ellard; Lee W Jones; Jinelle C Gelinas; J Douglass Rolf; Bernie Melzer; Samantha M Thomas; Pamela S Douglas; Michel G Khouri; Neil D Eves
Journal:  Oncologist       Date:  2016-01-13

8.  Exercise Intolerance in Anthracycline-Treated Breast Cancer Survivors: The Role of Skeletal Muscle Bioenergetics, Oxygenation, and Composition.

Authors:  Rhys I Beaudry; Amy A Kirkham; Richard B Thompson; Justin G Grenier; John R Mackey; Mark J Haykowsky
Journal:  Oncologist       Date:  2020-01-17

9.  Association between systolic ejection time and outcomes in heart failure by ejection fraction.

Authors:  Priyesh A Patel; Andrew P Ambrosy; Matthew Phelan; Fawaz Alenezi; Karen Chiswell; Melissa K Van Dyke; Jennifer Tomfohr; Narimon Honarpour; Eric J Velazquez
Journal:  Eur J Heart Fail       Date:  2019-12-21       Impact factor: 15.534

10.  Subclinical ventricular dysfunction detected by speckle tracking two years after use of anthracycline.

Authors:  André Luiz Cerqueira de Almeida; Viviane Almeida Silva; Alberto Teófilo de Souza Filho; Vinicius Guedes Rios; João Ricardo Pinto Lopes; Samuel Oliveira de Afonseca; Daniel de Castro Araújo Cunha; Murilo Oliveira da Cunha Mendes; Danilo Leal Miranda; Edval Gomes dos Santos Júnior
Journal:  Arq Bras Cardiol       Date:  2015-01-27       Impact factor: 2.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.